Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

SocGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca. Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta. It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently...
AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

SoGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca (LON:AZN).

Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta.

It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently projecting.

However, it sees challenges for Brilinta: “Our forecasts for sales are significantly below consensus because we see multiple hurdles to its use in the US, such as the negative US data from the PLATO study, which deters doctors from prescribing it, an unhelpful twice daily dosing regimen, and an interaction with statins (which is absent in competitors clopidogrel and Effient).”

At midday the shares were changing hands for £30.67, down 9.5p on the day.

 



Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

Article
December 28 2015

Related Articles

Lab_56a610b229ca5.jpg
January 25 2016
Broker N+1 Singer said: “The licensing agreement with a large US biotech is excellent news and illustrates the commercial potential of Abzena’s ThioBridge platform for the design of better antibody-drug conjugate drugs.”
blood_56ceb82789b61.jpg
February 25 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
Test-tubes_opt_56d69b8aa24bf.jpg
March 02 2016
The company's results reveal a company in rude health - and one still on the acquisition trial.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.